Allt inom Corporate Information
All patients in Nanexa Phase 1 study of NEX-22 dosed according to plan
Nanexa AB today announces that dosing of the last patient has been completed in the Phase 1 study of the long-acting depot formulation of the GLP-1 analog liraglutide PharmaShell®.
Nanexa starts the final dose group in the Phase 1 study of NEX-22 for treatment of Type 2 Diabetes
Nanexa AB today announces that the first patient in the third dose group with their long-acting depot formulation of the GLP-1 analog liraglutide has been dosed. The study started in Jun 2024 and have so far studied two consecutive dose groups with escalating doses.